Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,834 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome.
Raghuram N, Hasegawa D, Nakashima K, Rahman S, Antoniou E, Skajaa T, Merli P, Verma A, Rabin KR, Aftandilian C, Kotecha RS, Cheuk D, Jahnukainen K, Kolenova A, Balwierz W, Norton A, O'Brien M, Cellot S, Chopek A, Arad-Cohen N, Goemans B, Rojas-Vasquez M, Ariffin H, Bartram J, Kolb EA, Locatelli F, Klusmann JH, Hasle H, McGuire B, Hasnain A, Sung L, Hitzler J. Raghuram N, et al. Among authors: nakashima k. Blood Adv. 2023 Nov 14;7(21):6532-6539. doi: 10.1182/bloodadvances.2022009381. Blood Adv. 2023. PMID: 36735769 Free PMC article.
Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D, Moritake H, Hama A, Nakashima K, Kanezaki R, Kudo K, Saito AM, Horibe K, Adachi S, Tomizawa D, Ito E. Terui K, et al. Among authors: nakashima k. Genes Chromosomes Cancer. 2020 Mar;59(3):160-167. doi: 10.1002/gcc.22816. Epub 2019 Oct 21. Genes Chromosomes Cancer. 2020. PMID: 31606922
A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20).
Tomizawa D, Tsujimoto SI, Tanaka S, Matsubayashi J, Aoki T, Iwamoto S, Hasegawa D, Nagai K, Nakashima K, Kawaguchi K, Deguchi T, Kiyokawa N, Ohki K, Hiramatsu H, Shiba N, Terui K, Saito AM, Kato M, Taga T, Koshinaga T, Adachi S. Tomizawa D, et al. Among authors: nakashima k. Jpn J Clin Oncol. 2022 Oct 6;52(10):1225-1231. doi: 10.1093/jjco/hyac105. Jpn J Clin Oncol. 2022. PMID: 35809896 Clinical Trial.
2,834 results